Amendments to the Specification

Please replace the paragraph at page 14, lines 13-26 with the following amended paragraph:

In a preferred embodiment, the "P" component in the compounds of the invention is designed based upon the amino acid sequence of an "Aβ aggregation core domain" (ACD). As used herein, the term "Aβ aggregation core domain" refers to a subregion of a natural β-amyloid peptide that is sufficient to modulate aggregation of natural β-APs when this subregion, in its L-amino acid form, is appropriately modified (*e.g.*, modified at the amino-terminus), as described in detail in U.S. patent application Serial No. 08/548,998, now abandoned, and U.S. patent application Serial No. 08/616,081, now abandoned, the entire contents of each of which are expressly incorporated herein by reference. Preferably, the "P" component in the compounds of the invention is or is modeled after a subregion of natural β-AP that is less than 15 amino acids in length and more preferably is between 3-10 amino acids in length. In various embodiments, the "P" component in the compounds of the invention is, or is modeled after, a subregion of β-AP that is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more amino acids in length.

Please replace the paragraph at page 6, lines 6-9 with the following paragraph:

Figures 2A-L depicts an immunohistochemistry analysis of coronal brain sections from 20-22 week mice transgenic for both the Swedish mutation of amyloid precursor protein and presenilin of mouse IgG1 fused to various segments of β-amyloid, medium from nontransfected COS cells, or anti-β-amyloid polyclonal antibody.

Please replace the paragraph at page 6, lines 25-27 with the following paragraph:

Figures 8A-B ~~is a~~ are graphs demonstrating that Fc receptor-mediated fibril uptake by cells occurs in the presence of either the Aβ(16-30)-Fc fusion protein or the α-β-amyloid antibody.